Capabilities

We provide testing services to certify product and materials compliance, support quality control, and ensure the health and safety of workers and their environment. We provide assistance for clients who are not sure what tests they need. Our accredited materials characterization laboratory is the foundation of all the services of RJ Lee Group provides, including standardized testing for compliance, industrial hygiene and environmental analyses, quality control, and materials research and development.

We provide credentialed expertise supported built by robust scientific data. We provide significant support to industrial clients for product development, industrial hygiene and overall production support.

RJ Lee Group maintains a visible and respected reputation within the legal community, having offered scientific support in civil litigation matters for nearly 30 years. 

  • Product Liability 
  • Toxic Tort
  • Construction Defect
  • Fugitive Emission
  • Personal Injury
  • Patent Infringement
  • Contract Disputes
  • Insurance Subrogation

Subject Matter Experts

From our core business of providing scientific solutions to our clients, we have developed innovative products. Some are produced internally, and some have arisen from partnerships with other research organizations. 

For example, we build lab software solutions to help manage and streamline your labs data, and environmental testing products for a variety of applications. 

  • IntelliSEM is a powerful automated particle analysis system.
  • ParticleID is  a customizable cloud hosted web application used to identify foreign particulate matter and  assist with root cause investigations. 

Other products we create count particles and help keep the air and environment safe.

RJ Lee Group is a materials analysis laboratory and consulting company which serves many different industries. We offer scientific solutions such as industrial forensics services, laboratory and testing services, litigation support, and laboratory software to many industries:

Working Together to Prevent Pharmaceutical Counterfeiting

RJ Lee Group News

December 13, 2013

Counterfeit drugs are a significant threat — to patient safety, to public health, to supply chain integrity — raising concerns over potential liability for consumers, manufacturers, distributors, pharmacies, governments, and other entities.

As supply chains become more complex and global, efforts to combat the use of counterfeit drugs pose new challenges. In 2010 alone, counterfeit drugs generated an estimated $75 billion in revenue according to the National Association of Boards of Pharmacy. A recent literature review involving counterfeit medicines reported that between the years 2002 and 2012 incidents involving counterfeit drugs increased from 196 to 2,018. Increased counterfeiting of pharmaceuticals is due to several factors, including:

  • Size and value of the pharmaceutical market
  • Foreign sourcing and manufacturing
  • Drug shortage and demand (including abuse)
  • Ease of counterfeiting and high payoff
  • Low risk of consequences or penalties

In an effort to deter counterfeiting, Dr. Crystal Morrison Densmore of RJ Lee Group has partnered with DNA Technologies to develop solutions for the pharmaceutical and medical device industry. DNA Technologies offers an anti-counterfeiting solution to the marketplace through its combination of synthetic, DNA-laced security markers that can encode company and product-specific information into inks, dyes, and resins to provide the ultimate security marker – the DNA MatrixTM. DNA Technologies has become a leader in providing security marking and unequalled protection for valuable products, brands, and intellectual property.

Dr. Morrison Densmore’s collaboration with DNA Technologies pairs her expertise in materials with a recognized leader in protection against counterfeiting and product diversion. Together, the team will leverage extensive expertise in materials science, the pharmaceutical industry, and industrial forensics with DNA Technologies’ experience in printing, covert and overt security marking and counterfeit deterrence, in order to deliver critical solutions to challenges facing pharma. The team will use DNA Matrix™ technology to develop a truly robust anti-counterfeiting system that layers multi-dimensional overt, covert, and forensic features.

Without multi-dimensional features, preventing counterfeiting is almost impossible.

In basic form, 2D barcodes are an overt readable method for identification and tracking. They can be effective for streamlining provider immunization practices and efficient information capture. However, drug companies need to incorporate additional features in layers for real security.

“We are pleased to partner with Dr. Morrison Densmore,” commented Wendell Smith, Chairman of DNA Technologies. “With the growth of the global supply of counterfeit drugs, there is no easy solution to the counterfeiting problem, but pharmaceutical companies, distributors, governments and companies like us, all have important roles to play. It is clear that industry needs to establish a more formalized system for tracking, sourcing and security information to combat the counterfeit threat. This is the basis for our collaboration.”

Related Posts